Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. Purchases New Position in Soleno Therapeutics, Inc. $SLNO

Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. acquired a new stake in shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 502,374 shares of the company’s stock, valued at approximately $42,089,000. Soleno Therapeutics accounts for about 4.9% of Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A.’s investment portfolio, making the stock its 5th biggest holding.

Other hedge funds have also added to or reduced their stakes in the company. Optimize Financial Inc purchased a new position in shares of Soleno Therapeutics during the first quarter valued at about $274,000. Scientech Research LLC grew its holdings in shares of Soleno Therapeutics by 120.5% during the 1st quarter. Scientech Research LLC now owns 11,620 shares of the company’s stock worth $830,000 after acquiring an additional 6,351 shares during the period. GAMMA Investing LLC grew its holdings in shares of Soleno Therapeutics by 4,377.3% during the 1st quarter. GAMMA Investing LLC now owns 3,358 shares of the company’s stock worth $240,000 after acquiring an additional 3,283 shares during the period. Woodline Partners LP grew its holdings in shares of Soleno Therapeutics by 16.0% during the 1st quarter. Woodline Partners LP now owns 349,664 shares of the company’s stock worth $24,983,000 after acquiring an additional 48,102 shares during the period. Finally, Oppenheimer & Co. Inc. purchased a new position in shares of Soleno Therapeutics during the 1st quarter worth approximately $232,000. 97.42% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on SLNO. Guggenheim reaffirmed a “buy” rating and issued a $106.00 price target on shares of Soleno Therapeutics in a research note on Wednesday, August 27th. TD Cowen started coverage on Soleno Therapeutics in a research note on Monday, June 23rd. They issued a “buy” rating and a $110.00 price target on the stock. The Goldman Sachs Group set a $125.00 target price on shares of Soleno Therapeutics and gave the stock a “buy” rating in a research report on Tuesday. Cowen reaffirmed a “buy” rating on shares of Soleno Therapeutics in a research report on Thursday, August 7th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Soleno Therapeutics in a research report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Soleno Therapeutics has an average rating of “Moderate Buy” and an average price target of $115.92.

Soleno Therapeutics Trading Down 2.7%

Shares of SLNO stock opened at $63.76 on Friday. Soleno Therapeutics, Inc. has a 12-month low of $41.50 and a 12-month high of $90.32. The company has a current ratio of 15.13, a quick ratio of 15.01 and a debt-to-equity ratio of 0.21. The firm’s 50 day moving average is $66.76 and its 200 day moving average is $73.54. The stock has a market capitalization of $3.39 billion, a P/E ratio of -15.40 and a beta of -2.75.

Soleno Therapeutics (NASDAQ:SLNO) last announced its earnings results on Wednesday, August 6th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.53) by $0.44. The firm had revenue of $32.66 million during the quarter, compared to analysts’ expectations of $3.91 million. Research analysts expect that Soleno Therapeutics, Inc. will post -3.72 earnings per share for the current year.

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.